Larsen RH, Kolstad A, Fosså A, Repetto-Llamazares A, Smerud KT, Illidge T, Bruland ØS(2026) A Phase II Study of 177Lu-Lilotomab Satetraxetan, a CD37 Antibody-Radionuclide Conjugate, as Third- or Later-Line Treatment of Rituximab-Refractory Follicular B-Cell Lymphoma Patients Pharmaceuticals (Basel), 19(2) DOI 10.3390/ph19020250, PubMed 41754790
Lia K, Galleberg RB, Rostoft S, Jørgensen RRK, Smeland KB, Hjermstad MJ, Sørland K, Fagerli UM, Bø IB, Johansen J, Bhargava S, Kiserud CE, Fosså A(2026) Self-reported late effects, daily functioning, and health-related quality of life in older Hodgkin lymphoma survivors - a national population-based cross-sectional survey Leuk Lymphoma, 1-11(in press) DOI 10.1080/10428194.2026.2633180, PubMed 41761714
Willumsen LH, Smeland KB, Eikeland S, Fosså A, Bersvendsen HS, Fagerli UM, Falk RS, Lie HC, Skaali T, Kiserud CE(2026) Self-reported late effects and chronic fatigue, information needs and follow-up in long-term survivors of Hodgkin lymphoma-a cross-sectional study Support Care Cancer, 34(5) DOI 10.1007/s00520-026-10625-x, PubMed 41951854
